About
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Current Value
$318.691 Year Return
Current Value
$318.691 Year Return
Key Details
Market Cap
$7.22B
P/E Ratio
-14.8
1Y Stock Return
35.47%
1Y Revenue Growth
-
Dividend Yield
0.00%
Price to Book
9.5
Strategies that include MDGL
Double maintains 1 strategies that include MDGL - Madrigal Pharmaceuticals, Inc.
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to MDGL
The stocks that are correlated to MDGL - Madrigal Pharmaceuticals, Inc. are TILE, EYE, PRLB, MTZ, GSAT
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
 TILEInterface, Inc. | 40.25% | $1.10B | +14.29% | 0.22% |
| 39.29% | $893.01M | -44.16% | 0.00% | |
 PRLBProto Labs, Inc. | 37.26% | $806.24M | -2.06% | 0.00% |
 MTZMasTec, Inc. | 33.87% | $8.88B | +21.77% | 0.00% |
 GSATGlobalstar, Inc. | 33.81% | $2.48B | -1.50% | 0.00% |
| 33.67% | $6.11B | +9.06% | 0.00% | |
 WATWaters Corp. | 33.41% | $20.50B | +3.25% | 0.00% |
| 32.83% | $2.69B | -10.69% | 0.00% | |
 COHUCohu, Inc. | 32.57% | $640.86M | -56.61% | 0.00% |
| 32.17% | $6.58B | -27.28% | 0.00% | |
| 31.95% | $545.16M | -31.38% | 0.00% | |
| 31.71% | $5.70B | -18.63% | 0.00% | |
| 31.61% | $592.86M | -77.74% | 0.00% | |
| 30.99% | $1.29B | -23.75% | 0.00% | |
| 30.98% | $579.42M | -22.80% | 0.00% | |
| 30.45% | $817.37M | -37.06% | 0.00% | |
| 30.11% | $3.16B | -13.91% | 0.50% | |
 QTRXQuanterix Corp. | 30.08% | $240.80M | -71.25% | 0.00% |
 TWLOTwilio, Inc. | 29.92% | $13.67B | +48.89% | 0.00% |
| 29.84% | $3.15B | +24.24% | 0.00% | |
ETF's related to MDGL
The ETFs that are correlated to MDGL - Madrigal Pharmaceuticals, Inc. are ETH, QETH, CETH, ETHW, EZET
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 43.75% | $1.29B | 0% | |
| 43.11% | $14.37M | 0.25% | |
| 42.97% | $10.46M | 0% | |
| 42.94% | $178.38M | 0% | |
| 42.93% | $22.41M | 0% | |
| 42.92% | $2.25B | 0.25% | |
| 42.57% | $761.54M | 0.25% | |
| 42.57% | $87.80M | 0% | |
| 42.11% | $110.09M | 0.6% | |
| 41.43% | $5.06B | 0.35% | |
| 40.06% | $294.73M | 0% | |
| 36.57% | $5.70B | 0.45% | |
| 36.43% | $987.53M | 0.75% | |
| 35.53% | $48.48M | 0.5% | |
| 33.98% | $1.09B | 0.56% | |
| 33.62% | $63.83M | 0.8% | |
| 33.47% | $34.93M | 0.68% | |
| 33.28% | $48.65M | 0.69% | |
| 32.38% | $534.69M | 0.3% | |
| 32.37% | $1.85B | 0.78% | |
News
Finnhub
Doc# VV-QUAL-01910 Version: 1.0 Corporate Policy: Anti-Bribery and Anti-Corruption Policy DOCUMENT TITLE: ...
SeekingAlpha
Bumbershoot had over 10+ companies drop more than -15% in Dec. 2024. So, why does Bumbershoot actually believe 2024 was a solid year? Find out.
Yahoo
We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against other most expensive stocks insiders are dumping in March. After being in the green for a few trading sessions, the broader market […]
Yahoo
In the last week, the United States market has stayed flat, but it is up 7.8% over the past year with earnings forecast to grow by 14% annually. In this context of steady growth and positive projections, identifying high growth tech stocks involves looking for companies with innovative products and strong potential to capitalize on emerging trends within the tech sector.
SeekingAlpha
The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to read the full commentary.
SeekingAlpha
John Paulson's 13F portfolio increased from ~$1.43B to ~$1.65B. Click here to read more about significant stake increases and notable positions of the holdings.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds